Conversely, the administration of SFRP5 in mouse models of obesity and diabetes yields contrasting outcomes, enhancing metabolic functionality and mitigating inflammation within adipose tissue [16]. This evidence concerns the gene SFRP5 and obesity due to melanocortin 4 receptor deficiency.